不同复方短效口服避孕药治疗痛经的临床疗效分析

不同复方短效口服避孕药治疗痛经的临床疗效分析

刘林丽,林舟

福州市第一医院,福州市第一医院

收稿日期:2019-05-06 修回日期:2019-07-13 出版日期:2019-08-28 发布日期:2019-08-28
基金资助:
福州市科技局基金项目资助(编号：2018-S-105-4和2017-S-129-3)，福建省自然引导性基金项目资助（编号：2019D004）

Effect of Different Conbination Oral Contraceptives in the Treatment of Dysmenorrhea

LIU Linli and

Affiliated Fuzhou First Hospital?of Fujian Medical university,Affiliated Fuzhou First Hospital?of Fujian Medical university

Received:2019-05-06 Revised:2019-07-13 Online:2019-08-28 Published:2019-08-28

摘要/Abstract

摘要： 目的：探讨4种短效避孕药治疗痛经的临床效果。方法：将我院231名患者随机分配到妈富隆组(A组)、达英-35组(B组)、优思明组(C组)、优思悦组(D组)及安慰剂组(F组)。应用TDS法、VAS法统计并观察各组在服药前、服用1周期、3周期、6周期时疼痛评分、疼痛缓解情况和不良情况发生率。结果：5组总有效率分别为90.2%、93.8%、95.9%、92.5%、16.7%，差异有统计学意义。痛经患者服用避孕药后1周期、3周期、6周期时TDS、VAS疼痛评分均较应用前明显降低，差异有统计学意义（P<0.05）。治疗后各组患者出现的总体不良反应率分别为45.1%、45.8%、42.9%、24.55%、6.7%，总体差异有统计学意义(χ2=19.216，P<0.05)，卡方分割后发现优思悦组总不良反应率低于其妈富隆组、达英-35组和优思明组（χ2=4.859，P=0.028；χ2=13.296，P=0；χ2=3.849，P=0.005）。结论：短效口服避孕药治疗痛经疗效确切，而优思悦不良反应发生率相对少，治疗痛经的总体疗效也优于其余3种避孕药。

Abstract: Objective：To analyze clinical effect of the four kinds of short-acting contraceptives in the treatment of dysmenorrhea. Methods：231 patients with dysmenorrheal treated in our hospital from January 2017 to December 2018 were selected and randomly divided into group A，group B，group C，group D and group F according to the random number table method．group A，groupB，groupc，groupd and group F was given contraceptives Marvelon，Diane 35，Yasmin，YAZ and placebo for 6 cycles respectively.The effects of the five groups were observed and compared. Results：The total efficiency rate of the five groups was 90.2%、93.8%、95.9%、92.5% and 16.7% respectively，with statistically significant difference.The scores of TDS and VAS in group A，group B，group C and group D were significantly lower after 1， 3 and 6 cycles of contraceptive than before treatment.The overall adverse reaction rates were 45.1%， 45.8%， 42.9%， 24.55% and 6.7%， respectively. The overall difference was statistically significant (χ2=19.216， P<0.05).After chi-square segmentation， the total adverse reaction rate of the group D was lower than that of the group A， group B and group C (χ2=4.859， P=0.028； χ2=13.296， P=0； χ2=3.849， P=0.005). Conclusion：Short-acting oral contraceptives are efficient in treating patients with dysmenorrhea， while the incidence of adverse reactions ofYAZ is relatively lower. The overall efficacy of the treatment of dysmenorrhea is also better than the other three contraceptives.

刘林丽,林舟. 不同复方短效口服避孕药治疗痛经的临床疗效分析[J]. .

LIU Linli and. Effect of Different Conbination Oral Contraceptives in the Treatment of Dysmenorrhea[J]. .

参考文献

[1]顾美皎，戴钟英，魏丽惠. 临床妇产科学[M]. 2 版. 北京：人民卫生出版社， 2011：542-544. [2]杨琼秀，熊平安．单纯口服避孕药用于原发性痛经的临床疗效[J]. 武汉大学学报( 医学版)，2011，32(4)：555-557，563. [3]武孟香，许燕丽，刘丽萍，等．妈富隆治疗原发性痛经的初步研究[J]. 齐齐哈尔医学院学报，2012，33(1)：13-15. [4]史惠蓉. 现代口服避孕药安全性的循证医学支持[J]. 实用妇产科杂志，2009，25(2)：73-74. [5]Das S， Reynolds RV. Recent Advances in Acne Pathogenesis：Implications for Therapy[J]. Am J Cli Dermatol， 2014， 15(6)：357-358. [6]Yonkers KA， Brown C， et al. Efficancy of allow-doseral contraceptive with drospirenone in premenstrual dysphric disorder[J]. Obstet Gynecol， 2015， 5(3)：492-501. [7]复方口服避孕药临床应用中国专家共识专家组．复方口服避孕药临床应用中国专家共识[J]．中华妇产科杂志，2015，50(2)：81-91. [8]王骁，熊承良.口服避孕药中雌激素的应用和进展[J]. 国际生殖健康/计划生育杂志，2013，32（4）：254-257. [9]Pearlstein TB， Bachmann GA， Zacur HA， et al. Treatment of premenstrualdysphoric disorder ntaining oral contraceptive formulatio[J]. Contraception 2005， 72(6)：414-421. [10]张静. 低剂量复方口服避孕药治疗痛经56 例临床观察[J]. 中国计划生育学杂志，2009，17(11)：688-689. [11]Vercellini P， Frontino G， De Giorgi O， et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen[J]. Fertil Steril， 2003，80(3)：560-563. [12]谢幸，苟文丽.妇产科学[M]. 第８版．北京：人民卫生出版社，2013，362-363， 377-380. [13]Parsey KS， Pong A. An open-label multicenter study to evaluate Yasmin 5a low-dose combination oral contraceptive containing drospirenone， a new progestogen[J]. Contraception， 2000， 61(2)：105-111. [14]Rubig A. Drospirenone：a new cardiovasular-active progesstin with antialdosterone and antianddrogentic properties[J]. Climacteric， 2013， 6(Suppl 3)：49-54. [15]Thomycrot H， Gollnick H. Superiority of a combined coonbined contraceptive containing drospirenone to a triphasic preparetion containing norgestimate in acnetreatment[J]. Cutis， 2004， 74(2)：　123-130． [16]Streuli I， de Ziegler D， Santulli P， et al. An update on the pharmacological management of endometriosis[J]. Expert Opin Pharmacother， 2013，14(3)：291-305. [17]王彩燕，狄文，廖秦平，等．屈螺酮炔雌醇片用于中国妇女避孕的多中心临床研[Ｊ]. 中华妇产科杂志，2014，49(5)：355-359. [18]Thomas， Strowitzki， Bodestradiol， et al. Efficacy of ethinylestradiol 20 μg·d-1 rospirenone 3 mg in a flexible extended regimen in women with moderate-to-severe primaty dysmenorrhone：an open-labeo，multicenter， randomised.controlled study[J]. Fam Plann Reprod Healthcare， 2012， 38(2)：94-101. [19]Tanaka Ys Mori T， et al. Effects of low-dose combined drospirenone-ethinylestradiol on perimenstrual symptoms experienced by women with endometriosis[J]. Int J Gynaeclo Obstet， 2016， 135(2)：135-139.